Back to the main directory
EarningsReview / Equity
- Roadshow feedback: very agile in a tougher market by BNP Paribas Exane
- Swedish Match (Hold, TP: SEK445.00) - Decent earnings but regulation risks by DnB Markets
- Rating under review by BNP Paribas Exane
- The Alchemist: tales from the US tapes by BNP Paribas Exane
- In the fields of Barley by BNP Paribas Exane
- Espresso | Akka Technologies | Hold | Expecting strong growth in Q4 by Kepler Cheuvreux
- Prosafe (Hold, TP: NOK18.00) - No surprises in Q4 by DnB Markets
- Ripasso Energy Exciting times ahead by DnB Markets
- Pandora (Hold, TP: DKK325.00) - Q4 above, 2019e hit by restructuring by DnB Markets
- WOOD Flash – Severstal: 4Q18 results – in line on EBITDA, but FCF falls 52% qoq on high working capital build up by Wood and Company
- Coloplast (Buy, TP: DKK700.00) - Q1 as expected by DnB Markets
- Outokumpu (No_rec, TP: EUR) - Discontinuing coverage by DnB Markets
- PreFlight Check: Airbus sets pace for a smoother year by BNP Paribas Exane
- Reality check ahead of annual results by BNP Paribas Exane
- BHEL (BHEL IN) by HSBC
- Higher costs, but still able to clean up by BNP Paribas Exane
- Espresso | Vivendi | Hold | FY earnings preview (results on afternoon of 14 February) by Kepler Cheuvreux
- Alfa Laval (Buy, TP: SEK250.00) - A hiccup does not make a trend by DnB Markets
- Capex keeps us cautious + questions for management by BNP Paribas Exane
- On target by BNP Paribas Exane
- MTG (Buy, TP: SEK365.00) - Steady in most places by DnB Markets
- Orkla (Hold, TP: NOK70.00) - Weak Q4 hit by restructuring by DnB Markets
- Investment Daily 06/02/2019 by BNP Paribas Exane
- Handicare (Buy, TP: SEK46.00) - Trend shift in Patient Handling by DnB Markets
- Fabege (Hold, TP: SEK125.00) - Q4 beat, but limited share price potential by DnB Markets
- Q2 sales short of expectations by BNP Paribas Exane
- Ryanair (RYA ID) by HSBC
- 360 Report | Komax | Reduce | Wired by Kepler Cheuvreux
- The Beer Ahead by BNP Paribas Exane
- Soft finish to 2018 and start to 2019 by BNP Paribas Exane
- Investment Daily 05/02/2019 by BNP Paribas Exane
- Lundbeck (Hold, TP: DKK290.00) - Guidance of declining growth by DnB Markets
- Atvexa by DnB Markets
- Atvexa Education roll-up accelerates by DnB Markets
- Cash flow helped by working capital by DnB Markets
- Fortum (No_rec, TP: EUR) - Discontinuing coverage by DnB Markets
- SSAB (No_rec, TP: SEK) - Discontinuing coverage by DnB Markets
- Lundbeck (Sell, TP: DKK270.00) - by DnB Markets
- Coloplast (Hold, TP: DKK700.00) - Wound & Skin secures revenue by DnB Markets
- Mexican SME Lenders by HSBC
- Pandora (Hold, TP: DKK325.00) - Passion needed by DnB Markets
- Valuation Station - Business as Usual by BNP Paribas Exane
- Nokian Tyres (Buy, TP: EUR34.00) - Central Europe target at risk by DnB Markets
- Commendations for 2018: Caution for 2019 by BNP Paribas Exane
- Epiroc (Buy, TP: SEK100.00) - Equipment orders are lumpy by DnB Markets
- Carlsberg (Sell, TP: DKK720.00) - by DnB Markets
- Big spender (and 15 qs) by BNP Paribas Exane
- ETUDE - ALTRAN : Les raisons de nos inquiétudes - VENTE, OC 7,1€ (vs 6,2€) by Invest Securities
- Nordic Semiconductor (Buy, TP: NOK52.00) - Excellent entry opportunity by DnB Markets
- Marico Industries (MRCO IN) by HSBC